<DOC>
	<DOC>NCT00199979</DOC>
	<brief_summary>The study will compare the immuno-virological efficacy, and safety, of a once daily antiretroviral combination (tenofovir + lamivudine + nevirapine) versus a twice daily association (fixed dose combination of zidovudine/lamivudine + nevirapine) in ARV-Naive HIV-1 infected subjects, with CD4 cell count below 350/µL or below 15%, whatever the viral load. Pharmacological (nevirapine concentrations) and virologic data (resistance mutations in case of failure) will also be provided, as well as adherence rate and quality of life in respect of the treatment arms.</brief_summary>
	<brief_title>Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients</brief_title>
	<detailed_description>96-week antiviral efficacy of tenofovir + lamivudine + nevirapine, once daily, versus a reference antiretroviral treatment given twice daily (zidovudine/lamivudine + nevirapine)</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV1 infection, confirmed by a westernblot assay, at least 6 months after primary infection Age &gt; or equal to 18 years of age No prior antiretroviral treatment Karnofsky superior to 60% CD4 T cells &lt; 350/µL (2 measures, with at least a 1month interval) in women, study will be proposed when CD4 cell count is below 250/µL, as nevirapine liver toxicity increases (X10) when CD4 are &gt; 250/µL Written informed consent HIV2 infection or coinfection Prior antiretroviral treatment Intolerance, or contraindication to investigational drugs Pregnant or breastfeeding woman, or plan to become pregnant Active untreated opportunistic infections (AIDSdefining illness, category C, CDC, 1993), or malignancies requiring cytotoxic chemotherapy Biological criteria: hemoglobin &lt; 10 G/DL, neutrophil count &lt; 1000/µL, platelets &lt; 50000/µL, creatinine &gt; 2N, ASAT or ALAT &gt; 2.5N, bilirubin &gt; 2N, hypophosphatemia Prevision of poor adherence HBC coinfection (Ag Hbs positive) or HVC coinfection (positive HCV PCR) Liver failure, alcohol abuse Treatment administration not recommended with investigational drugs Interferon, interleukin, or HIV vaccine treatment Informed consent not obtained</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Antiretroviral Therapy</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>HIV Viral Load</keyword>
	<keyword>Adherence</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>Resistance Mutations</keyword>
</DOC>